ProCE Banner Activity

Slideset: Pharmacotherapy of Bipolar Depressive Spectrum Disorders

Slideset Download

One of the most important needs in treating bipolar disorder is a proper diagnosis, where screening tools such as the Rapid Mood Screener can help. Second-generation antipsychotics have the most data in mixed features, and only lumateperone and quetiapine have proven efficacy data in bipolar II depression. Antidepressants may be safe and effective in certain patients, particularly those with bipolar II. Rapid-acting antidepressants such as ketamine are currently being studied.

Released: December 07, 2021

Share

Faculty

Roger McIntyre

Roger McIntyre, MD, FRCPC

Professor of Psychiatry and Pharmacology
University of Toronto, Canada
Chairman and Executive Director, Brain and Cognition Discovery Foundation
Toronto, Canada
Board Chair, Depression and Bipolar Support Alliance
Board of Directors
Chicago, Illinois

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from

AbbVie

Intra Cellular Therapies

Sunovion

Faculty Disclosure

Primary Author

Roger McIntyre, MD, FRCPC

Professor of Psychiatry and Pharmacology
University of Toronto, Canada
Chairman and Executive Director, Brain and Cognition Discovery Foundation
Toronto, Canada
Board Chair, Depression and Bipolar Support Alliance
Board of Directors
Chicago, Illinois

Roger McIntyre, MD, FRCPC, has disclosed that he has received speaker/consultation fees from Lundbeck, Janssen, Purdue, Pfizer, Otsuka, Takeda, Neurocrine, Sunovion, Bausch Health, Novo Nordisk, Kris, Eisai, Intra-Cellular, Abbvie. Dr. Roger McIntyre is CEO of Braxia Scientific Corp.